Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 153 of the 161 references it cites were found in a registry or an index; 18 of the 135 sources its claims cite were checked for support.

Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer

Open access

Abstract

Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.

Overview

CoChat Summary

## TL;DR

This paper is a review of aminolevulinic acid (ALA) as a prodrug for photodynamic therapy (PDT) in cancer, explaining how exogenous ALA leads to protoporphyrin IX (PpIX) accumulation and selective tumor killing after light exposure. It argues that ALA-PDT is a highly promising, clinically approved strategy, but its effectiveness is limited by poor penetration, pain, light depth, and variable PpIX accumulation.

## Key findings

  • Exogenous ALA bypasses normal heme-regulated control, causing PpIX to accumulate because ferrochelatase cannot convert it to heme quickly enough; light exposure after about 4–6 hours activates PpIX and generates cytotoxic singlet oxygen.
  • Tumor selectivity is linked to heme-pathway differences: decreased ferrochelatase activity, limited iron availability, and increased activity of PpIX-producing enzymes such as ALAD, UROD, and PBGD contribute to higher PpIX in tumors than in normal cells.
  • Reported clinical outcomes include 50%–100% complete responses for superficial basal cell carcinoma, 43% recurrence at 60 months, 100% response with no recurrence after 18 months in cutaneous T-cell lymphoma, and 68%–75% complete response after single MAL-PDT for actinic keratosis.
  • The paper states that at least 77 ALA modifications and carriers have been reported to improve delivery, reflecting strong interest in overcoming ALA’s limited skin and tissue penetration.

## Methods

  • Narrative review of the literature on ALA metabolism, pharmacokinetics, preclinical PDT studies, clinical indications, and ALA derivatives.
  • Synthesizes prior experimental and clinical studies in multiple systems, including cell lines, mouse and rat models, and human clinical trials.
  • Main analysis is qualitative: it compares reported mechanisms, delivery strategies, and treatment outcomes rather than presenting a new dataset or original statistical analysis.

## Limitations

  • The paper states that ALA-PDT is limited by light hypersensitivity, inefficiency for large or metastatic tumors, pain during treatment, and limited tissue penetration.
  • It also states that topical and even systemic ALA penetrate tissues only poorly, restricting efficacy; for topical use, PpIX fluorescence is seen only to a depth of 0.3 to 0.6 mm.
  • Evident from the text: this is a review, so its conclusions depend on prior studies and are not based on a single controlled experiment or newly collected patient cohort.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/molecules16054140

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Overview of PDT. Following photosensitizer administration it undergoes systemic distribution and selectively accumulates in the tumor. Illumination activates the photosensitizer and in the presence of molecular oxygen triggers a photochemical reaction that culminates in the production of 1O2.
Figure 1 Overview of PDT. Following photosensitizer administration it undergoes systemic distribution and selectively accumulates in the tumor. Illumination activates the photosensitizer and in the presence of molecular oxygen triggers a photochemical reaction that culminates in the production of 1O2.CC BY · PubMed Central
Figure 2 Types of oxidative reactions during PDT. Light with sufficient energy and wavelength matching absorption spectrum of the photosensitizer (PS) can activate a photochemical reaction that leads to formation of activated PS molecule (denoted by asterisk). Activated PS can lose its energy by emitting of visible light (fosforescence or fluorescence). Alternatively it may generate singlet oxygen in a type II reaction or free radicals in a type I reaction.
Figure 2 Types of oxidative reactions during PDT. Light with sufficient energy and wavelength matching absorption spectrum of the photosensitizer (PS) can activate a photochemical reaction that leads to formation of activated PS molecule (denoted by asterisk). Activated PS can lose its energy by emitting of visible light (fosforescence or fluorescence). Alternatively it may generate singlet oxygen in a type II reaction or free radicals in a type I reaction.CC BY · PubMed Central
Figure 3 Heme biosynthesis. The graphic presents the most important steps in the heme biosynthetic pathway.
Figure 3 Heme biosynthesis. The graphic presents the most important steps in the heme biosynthetic pathway.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 3 Not valid · 72 Not checked · 20 Own results and interpretations

43 more claims

Create a free account to see all 112 claims and to verify the 10 references still open.

See all claims — free account
  • It may state two separate claims as one. 45
  • Probably not a substantial claim. 29

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 161 references

Cited by

See all 265

Metadata

Authors
Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J.
Affiliations
  • Medical University of Warsaw (PL)
  • Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland
Venue
Molecules
Publisher
MDPI AG
Published
2011-05-19
Volume
16
Issue
5
Pages
4140-4164
ISSN
1420-3049 (ISSN-L)
OpenAlex
W1976436613
Cited by
265
References
161
Citations by year
2026: 5 · 2025: 14 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 24 · 2020: 36 · 2019: 23 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 10 · 2014: 13 · 2013: 4 · 2012: 9
FWCI
7.03
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fundacja na rzecz Nauki Polskiej
  • Servier
  • European Regional Development Fund (POIG. 01.01.02-00-008/08)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
5-aminolevulinic acid, photodynamic therapy, prodrugs, protoporphyrin IX, photosensitizers, ferrochelatase, heme biosynthesis, cancer therapy, heme oxygenase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. https://app.cochat.ai/papers/10.3390/molecules16054140
The paper
Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J. (2011). Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. Molecules. https://doi.org/10.3390/molecules16054140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.